Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rosiglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 12/20 | 1.00 |
| ▸ | RARG | P13631 | 1/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 1.00 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 6/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | PKM | P14618 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rosiglitazone SCHEMBL19023 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL29376790 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL19469505 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL466397 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL5556077 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL5734118 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL504723 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL29757195 | 1.00 | PPARG (1.00) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL3629161 | 0.99 | PPARG (0.98) | PPARGRARGRXRAPPARAKMT2A | |
| Rosiglitazone SCHEMBL3347673 | 0.99 | PPARG (0.98) | PPARGRARGRXRAPPARAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 807 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564728-B2 | Treatment of central nervous system disorders | KNOW BIO, LLC (US) | 2026-03-03 | — | — | US | claimed |
| US-20250092360-A1 | METHODS AND COMPOSITIONS FOR GENERATING SOMATOSTATIN+ INTERNEURONS FROM HUMAN FOREBRAIN NEURAL PROGENITOR CELLS | TRAILHEAD BIOSYSTEMS INC. | 2025-03-20 | — | — | US | claimed |
| US-12146156-B2 | Use of LRP2 agonists for generating myeloid-derived suppressor cells | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY (US) | 2024-11-19 | — | — | US | claimed |
| US-20230293565-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2023-09-21 | — | — | US | claimed |
| EP-4188378-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | The Governors of the University of Alberta (CA) | 2023-06-07 | — | — | EP | claimed |
| US-20220348869-A1 | Use of LRP2 Agonists for Generating Myeloid-Derived Suppressor Cells | WISTAR INST (US) | 2022-11-03 | — | — | US | claimed |
| EP-4057813-A1 | COMPOSITIONS AND METHODS FOR TREATING HUANGLONGBING DISEASE IN CITRUS | New Life Crop Sciences LLC (US) | 2022-09-21 | — | — | EP | claimed |
| US-20220280807-A1 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | KNOW BIO, LLC | 2022-09-08 | — | — | US | claimed |
| US-20220202950-A1 | COMPOSITIONS COMPRISING BACTERIALLY DERIVED INTACT MINICELLS FOR THERANOSTIC APPLICATIONS | ENGENEIC MOLECULAR DELIVERY PTY LTD (AU) | 2022-06-30 | — | — | US | claimed |
| EP-4010072-A2 | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | KNOW Bio, LLC (US) | 2022-06-15 | — | — | EP | claimed |
| CN-101167726-A | Rosiglitazone maleate dispersible tablet and preparation method thereof | NINGXIA KANGYA PHARMACY GROUP (CN) | 2008-04-30 | — | — | CN | claimed |
| EP-1756099-A1 | SYNTHESIS OF ANTIDIABETIC ROSIGLITAZONE DERIVATIVES | Cipla Ltd. (IN) | 2007-02-28 | — | — | EP | claimed |
| WO-2007022255-A2 | PHARMACEUTICAL FORMULATIONS FOR SUSTAINED RELEASE | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | WO | claimed |
| US-20060264639-A1 | Process | CIPLA LIMITED (IN) | 2006-11-23 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| WO-2005105794-A1 | SYNTHESIS OF ANTIDIABETIC ROSIGLITAZONE DERIVATIVES | CIPLA LIMITED (IN) | 2005-11-10 | — | — | WO | claimed |
| WO-2005021541-A2 | PROCESS FOR THE PRODUCTION OF POLYMORPHS OF ROSIGLITAZONE MALEATE | CIPLA LIMITED (IN) | 2005-03-10 | — | — | WO | claimed |
| US-20050014798-A1 | Polymorphous forms of rosiglitazone maleate | CHEMI SPA (IT) | 2005-01-20 | — | — | US | claimed |
| EP-1468997-A2 | Polymorphous forms of rosiglitazone maleate | CHEMI S.p.A. (IT) | 2004-10-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264639-A1 | Process | PPARG, PPARD, PPARA | PPARG 1/4885RARG 201/4885RXRA 202/4885 |
| US-20050014798-A1 | Polymorphous forms of rosiglitazone maleate | PPARD, PPARA, PPARG | PPARG 3/4885RARG 9/4885RXRA 6/4885 |
| US-12564728-B2 | Treatment of central nervous system disorders | BDNF, NTRK2, CNTN1 | PPARG 3211/4885RARG 2730/4885RXRA 3213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.